Skip to main content
. Author manuscript; available in PMC: 2009 Nov 17.
Published in final edited form as: Hematology Am Soc Hematol Educ Program. 2008:186–192. doi: 10.1182/asheducation-2008.1.186

Figure 4. Results of a pilot clinical trial of sildenafil for pulmonary hypertension in sickle cell disease (SCD).

Figure 4

Baseline measurements were made in 12 patients with SCD on hydroxyurea, and then they were treated with oral sildenafil (25 to 100 mg 3 times daily) for up to 6 months. Sildenafil therapy significantly decreased estimated pulmonary artery systolic pressure (A) and improved 6-min walk distance (B). (C) Time course of the effects of sildenafil on tricuspid regurgitant jet velocity. (D) Decrease in plasma NT-pro-BNP levels with sildenafil therapy.18